← All patents

US20240246903A1

Indanone and tetraloneketo or hydroxyl oximes as cancel therapeutics

University of Texas System

Abstract

Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ERβ selective and/or ERβ specific ligands.

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
Stanton McHardy
Priority date
May 04, 2021
Filing date
April 28, 2022
Publication date
July 25, 2024
Language
en
Metadata fetched
August 29, 2026 00:32